For in vitro models of oxidative-stress-related disorders, including cardiovascular disease [19], age-related macular degeneration [22], diabetic retinopathy [48], and neurodegenerative disease [49], eriodictyol inhibits oxidative injury through the upregulation of the Nrf2 network. This evidence concerns the gene NFE2L2 and age-related macular degeneration.